The debate over the need for enhanced disclosures surrounding intangible Research and Development (R&D) assets continues to gather momentum, as industry stakeholders recognize the diverse economic values these assets hold across different sectors. The Financial Accounting Standards Board (FASB) has responded by opening an invitation to comment on the matter through May 30, as it deliberates the potential inclusion of intangibles in its technical agenda.
Intangible assets such as intellectual property and brand reputation, when acquired through R&D, demand transparent disclosures concerning their associated risks. This information provides investors and users crucial insights into future earnings potential. Enhanced disclosure levels could significantly aid companies in effectively developing these intangible assets for commercial success, thereby supporting the needs of financial statement users.
Under current accounting practices, brand names like Disney and Amazon are often regarded as indefinite-lived assets, implying that their value doesn’t diminish over time and they aren’t amortized. Instead, these assets are presumed to grow in value as they are bolstered by sales efforts unless impacted by significant market shifts.
In contrast, other intangibles classified as definite-lived must be fair valued and amortized over their anticipated useful life, dependent on future cash flows. As part of this approach, companies must periodically assess these assets for impairment when market conditions indicate their carrying value may no longer be recoverable.
The life sciences industry presents a unique challenge, with distinct accounting rules due to third-party regulatory involvement. Unapproved R&D activities are generally expensed until regulatory approvals, like those from the Food and Drug Administration (FDA), are obtained. This standard aims to navigate uncertainties inherent in the regulatory approval process. The industry’s high failure rates during drug development projects further necessitate clear and prudent accounting practices.
While an unapproved R&D intangible asset is acquired, it’s often treated as an indefinite-lived asset under business combinations, despite the probability of FDA approval remaining uncertain. This approach calls for constant monitoring and annual fair value assessments, a process both costly and volatile, which may deter smaller companies from investing in necessary R&D innovations.
Amidst the complex landscape of intangible assets, expending R&D costs only upon achieving FDA approval offers a clearer path forward by aligning the asset’s capitalized status with its actual commercial viability. Moreover, revisiting the status of in-process research and development (IPR&D) assets to categorize them as definite-lived could alleviate the financial and logistical burden of continuous monitoring and reporting.
The full exploration of these complex issues can be explored in Stephen Rivera’s article on Bloomberg Tax.